Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.
Top Stages
1 past transactions
Sequenta
Acquisition in 2015
Sequenta is a biotechnology company focused on the development of clinical diagnostics that leverage innovative methods to assess immune system status. Founded in 2008 by previous entrepreneurs from ParaAllele BioScience, Sequenta employs advanced techniques to analyze the immune cell receptor genes, which exhibit significant variability in the human genome. This diversity is critical for understanding various health conditions and diseases, enabling Sequenta to provide insights that may influence numerous clinical decisions through a single, powerful assay. The company's approach capitalizes on the reduced costs of DNA sequencing, positioning Sequenta at the forefront of advancements in immune-related diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.